Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
10 2021
Historique:
received: 15 07 2021
accepted: 28 07 2021
pubmed: 5 8 2021
medline: 30 9 2021
entrez: 4 8 2021
Statut: ppublish

Résumé

To measure secondary attack rates (SARs) in prospectively followed household contacts of paediatric and adult cases of SARS-CoV-2 infection in England. Self-taken nasal swabs from household contacts of PCR confirmed cases of COVID-19  and blood samples  on day 35 were tested for evidence of infection with SARS-CoV-2 virus. The secondary attack rate (SAR) among 431 contacts of 172 symptomatic index cases  was 33% (95% confidence intervals [CI] 25-40) and was lower from primary cases without respiratory symptoms, 6% (CI 0-14) vs 37% (CI 29-45), p = 0.030. The SAR from index cases <11 years  was  25% (CI 12-38). SARs ranged from 16% (4-28) in contacts <11 years old to 36% (CI 28-45) in contacts aged 19-54 years (p = 0.119). The proportion infected who developed symptoms (78%) was similar by age (p = 0.44) though <19 year olds had fewer mean number of symptoms than adults (p = 0.001) and fewer reported loss of sense of taste or smell (p = 0.0001). There are high risks of  transmission of SARS-CoV-2 virus in the home, including those where infection is introduced by a child. The risk of children acquiring infection was lower than that in adults and fewer developed typical symptoms of Covid-19 infection.

Identifiants

pubmed: 34348116
pii: S0163-4453(21)00380-7
doi: 10.1016/j.jinf.2021.07.037
pmc: PMC8325949
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

483-489

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have declared no competing interest.  SdeL is the Director of the Royal College of General Practitioners Research and Surveillance, and hold a grant from AstraZeneca both funded through his university.

Auteurs

Elizabeth Miller (E)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: liz.miller@phe.gov.uk.

Pauline A Waight (PA)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: pauline.kaye@phe.gov.uk.

Nick J Andrews (NJ)

Data and Analytical Sciences, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: nick.andrews@phe.gov.uk.

Kelsey McOwat (K)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: kelsey.mcowat@phe.gov.uk.

Kevin E Brown (KE)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: kevin.brown@phe.gov.uk.

Katja Höschler (K)

National Infection Services Laboratories, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: Katja.hoschler@phe.gov.uk.

Samreen Ijaz (S)

National Infection Services Laboratories, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: samreen.ijaz@phe.gov.uk.

Louise Letley (L)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: louise.letley@phe.gov.uk.

Donna Haskins (D)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: donna.haskins@phe.gov.uk.

Mary Sinnathamby (M)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: mary.sinnathamby@phe.gov.uk.

Hannah Cuthbertson (H)

Immunoassay Laboratory, National Infection Service, Public Health England, Porton Down SP4 0JG, United Kingdom. Electronic address: hannah.cutherbertson@phe.gov.uk.

Bassam Hallis (B)

Immunoassay Laboratory, National Infection Service, Public Health England, Porton Down SP4 0JG, United Kingdom. Electronic address: bassan.hallis@phe.gov.uk.

Vaishnavi Parimalanathan (V)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG United Kingdom and Royal College of General Practitioners Research and Surveillance Centre, Euston Square, London NW1 2FB, United Kingdom. Electronic address: vp16@utas.edu.au.

Simon de Lusignan (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG United Kingdom and Royal College of General Practitioners Research and Surveillance Centre, Euston Square, London NW1 2FB, United Kingdom. Electronic address: simon.delusignan@phc.ox.ac.uk.

Jamie Lopez-Bernal (J)

PHE Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue, NW9 5EQ London, United Kingdom. Electronic address: Jamie.LopezBernal2@phe.gov.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH